Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + intensified decitabine early salvage therapy for relapsed/refractory acute myeloid leukemia
2022-502665-15-00Phase 2Authorised
- Sponsor
- University Hospital Tübingen
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and decitabine in acute myeloid leukemia (AML), sponsored by University Hospital Tübingen. Primary endpoint: Hematologic remission as best response after one or two cycles. Planned start May 2023; status: authorised.
02
Drugs
venetoclaxdecitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2022-502665-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502665-15-00.